I think the F18-labelled products will change things very significantly. They will facilitate a change in the overall manufacturing logistics associated with these diagnostic imaging products. We'll see ourselves moving from an environment where we're sourcing as much material today from the reactors, to an environment where perhaps we're sourcing less material from reactors. As we look at our own pipeline, we're very focused on the development of F18-labelled compounds. The problem with them is the manufacturing infrastructure isn't in place today, nor is there the camera infrastructure in place to really be able to support significant deployment of that imaging modality, especially for cardiac in the future.
So there will continue to be a significant reliance on molybdenum-99 in these reactor producers while this F18 network is being deployed in the future. At the same time, as we look at our own products, we don't see those necessarily being a replacement for the current mo-99-based products, or the tc-99m-based products. We see them being a solution that maybe sits in the middle between that SPECT scan and the more invasive cardiac catheterization that Dr. Turcotte spoke about, to decrease and deal with the issues such as co-morbidities associated with those more invasive procedures.
So we always see an environment where mo-99 is required and is an important isotope, but we also see an environment where PET will play an increasing role as the products are developed and the infrastructure is developed to support them.